Last reviewed · How we verify
NCT05883865
Safety Study of Fenofibrate During Pregnancy
trial testing Fenofibrate in Severe Hypertriglyceridemia During Pregnancy in 250 participants. Status unknown.
1 June 2024
Quick facts
| Lead sponsor | First People's Hospital of Hangzhou |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 1 June 2022 |
| Primary completion | 1 June 2024 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Fenofibrate (FENOFIBRATE) — full drug profile →
Conditions studied
- Severe Hypertriglyceridemia During Pregnancy — all drugs for Severe Hypertriglyceridemia During Pregnancy →
Sponsor
First People's Hospital of Hangzhou
Who can join
Adults 20 to 45, female only, with Severe Hypertriglyceridemia During Pregnancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety of fenofibrate in severe hypertriglyceridemia pregnant women.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05883865
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fenofibrate
Trials testing the same drug.
- NCT07296458 — FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy · Phase 3 · recruiting
- NCT06858332 — Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia · recruiting
- NCT06191133 — Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma · Phase 1 · recruiting
- NCT06591455 — A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis · EARLY_PHASE1 · completed
- NCT06155331 — Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Br · Phase 2 · completed
Other First People's Hospital of Hangzhou trials
Trials by the same sponsor.
- NCT07507825 — Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) · Phase 2 · not yet recruiting
- NCT07390981 — Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder · NA · not yet recruiting
- NCT07242443 — Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Py · Phase 4 · not yet recruiting
- NCT07207278 — Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma · recruiting
- NCT06933992 — Safety and Efficacy of Chocolate Balloon Catheter in Peripheral Arterial Disease (CHOCO-PAD) · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05883865 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First People's Hospital of Hangzhou
- Last refreshed: 1 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05883865.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing